156 related articles for article (PubMed ID: 34617617)
1. Antibody incidence and red blood cell transfusions in patients on daratumumab.
Tauscher C; Moldenhauer S; Bryant S; DiGuardo M; Jacob EK
Transfusion; 2021 Dec; 61(12):3468-3472. PubMed ID: 34617617
[TBL] [Abstract][Full Text] [Related]
2. Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab.
Ye Z; Wolf LA; Mettman D; Plapp FV
Vox Sang; 2020 Feb; 115(2):207-212. PubMed ID: 31729042
[TBL] [Abstract][Full Text] [Related]
3. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
Phou S; Costello C; Kopko PM; Allen ES
Transfusion; 2021 Jul; 61(7):2054-2063. PubMed ID: 33960433
[TBL] [Abstract][Full Text] [Related]
4. Use of an in-house trypsin-based method to resolve the interference of daratumumab.
Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA
Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116
[TBL] [Abstract][Full Text] [Related]
5. Resolving the daratumumab interference with blood compatibility testing.
Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
[TBL] [Abstract][Full Text] [Related]
6. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing.
Chinoca Ziza KN; Paiva TA; Mota SR; Dezan MR; Schmidt LC; Brunetta DM; Ricci G; Basques FV; Barroso-Duarte F; Rocha V; Mendrone-Junior A; Dinardo CL
Transfusion; 2019 May; 59(5):1827-1835. PubMed ID: 30779172
[TBL] [Abstract][Full Text] [Related]
7. The impact of Daratumumab on transfusion service costs.
Cushing MM; DeSimone RA; Goel R; Hsu YS; Parra P; Racine-Brzostek SE; Degtyaryova D; Lo DT; Morrison M; Crowley KM; Rossi A; Vasovic LV
Transfusion; 2019 Apr; 59(4):1252-1258. PubMed ID: 30620407
[TBL] [Abstract][Full Text] [Related]
8. Screening for new red blood cell alloantibodies after transfusion in patients with sickle cell disease.
Rankin A; Darbari D; Campbell A; Webb J; Mo YD; Jacquot C; Delaney M; Luban NLC; Nickel RS
Transfusion; 2021 Aug; 61(8):2255-2264. PubMed ID: 34002408
[TBL] [Abstract][Full Text] [Related]
9. Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti-idiotype antibody.
Aung F; Spencer J; Potter D; Pham TD; Farooqui N; Platt KR; Zayat R; Oliveira M; Smeland-Wagman R; Petersen E; Kaufman RM
Transfusion; 2022 Aug; 62(8):1511-1518. PubMed ID: 35866570
[TBL] [Abstract][Full Text] [Related]
10. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).
Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y
Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414
[TBL] [Abstract][Full Text] [Related]
11. The Challenges of Daratumumab in Transfusion Medicine.
Dizon MF
Lab Med; 2017 Feb; 48(1):6-9. PubMed ID: 27794527
[TBL] [Abstract][Full Text] [Related]
12. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
Chari A; Arinsburg S; Jagannath S; Satta T; Treadwell I; Catamero D; Morgan G; Feng H; Uhlar C; Khan I; Doshi P; Usmani S
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):44-51. PubMed ID: 29054515
[TBL] [Abstract][Full Text] [Related]
13. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.
Chapuy CI; Aguad MD; Nicholson RT; AuBuchon JP; Cohn CS; Delaney M; Fung MK; Unger M; Doshi P; Murphy MF; Dumont LJ; Kaufman RM;
Transfusion; 2016 Dec; 56(12):2964-2972. PubMed ID: 27600566
[TBL] [Abstract][Full Text] [Related]
14. Immune erythrocyte antibodies in adult patients with sickle cell disease and blood donors in Lagos, Nigeria: a comparative study.
Adewoyin AS; Daramola OA; Ogbenna AA; Adeyemo TA
Immunohematology; 2021 Sep; 37(3):131-137. PubMed ID: 34591378
[TBL] [Abstract][Full Text] [Related]
15. Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy.
Anani WQ; Marchan MG; Bensing KM; Schanen M; Piefer C; Gottschall JL; Denomme GA
Transfusion; 2017 Jun; 57(6):1470-1479. PubMed ID: 28150308
[TBL] [Abstract][Full Text] [Related]
16. Intensive red blood cell transfusions and risk of alloimmunization.
Zalpuri S; Middelburg RA; Schonewille H; de Vooght KM; le Cessie S; van der Bom JG; Zwaginga JJ
Transfusion; 2014 Feb; 54(2):278-84. PubMed ID: 23782244
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab Interference in Pretransfusion Testing Is Overcome by Addition of Daratumumab Fab Fragments to Patients' Plasma.
Werle E; Ziebart J; Wasmund E; Eske-Pogodda K
Transfus Med Hemother; 2019 Dec; 46(6):423-430. PubMed ID: 31933572
[TBL] [Abstract][Full Text] [Related]
18. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
19. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Sanz C; Nomdedeu M; Belkaid M; Martinez I; Nomdedeu B; Pereira A
Transfusion; 2013 Apr; 53(4):710-5. PubMed ID: 22845746
[TBL] [Abstract][Full Text] [Related]
20. Blood component administration to multiple myeloma patients treated with daratumumab: suggesting a novel approach with use of 0.1 M dithiothreitol.
Pandey P; Setya D; Kaul E; Ranjan S; Singh MK; Shankar A
Immunohematology; 2020 Dec; 36(4):157-165. PubMed ID: 33544622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
